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Objective 
1. Discuss the clinical impact of pharmacist interventions in implementing 
prescribing criteria for calcitonin at Baptist Hospital of Miami 
Hypercalcemia
Classifications of hypercalcemia: 
Mild= Corrected serum 
calcium < 12 mg/dL 
Moderate= Corrected 
serum calcium 12-14 mg/dL
Severe= Corrected serum 
calcium >14 mg/dL 
Clinical condition defined as serum calcium levels exceeding the upper 
limit of normal (10.5 mg/dL).
Carroll MF, Schade DS.Am Fam Physician.2003;67:1959-66.
Regulation of Calcium in the Plasma 
 Parathyroid Hormone (PTH) Increases serum calcium levels 
 Stimulates production of vitamin D within the kidney 
 Facilitates mobilization of calcium from bone 
 Maximizes tubular reabsorption of calcium within the kidney 
 1,25-dihydroxyvitamin D3 (Calcitriol)  Increases serum calcium levels 
 Facilitates absorption of calcium from the small intestine 
 Enhances reflux of calcium out of bone 
 Calcitonin Reduces serum calcium levels 
 Secreted from thyroid gland in response to an increase in calcium blood concentrations  
 Promotes renal excretion of calcium 
Carroll MF, Schade DS.Am Fam Physician.2003;67:1959-66.
Etiology of Hypercalcemia 
Primary hyperparathyroidism Malignancy-associated hypercalcemia 
Vitamin D intoxication 
Medications 
• Thiazide diuretics 
• Lithium
• Calcium containing antacids 













moderate (symptomatic) & 
severe hypercalcemia
First-line therapy 
Carroll MF, Schade DS.Am Fam Physician.2003;67:1959-66.
First-line therapy 
Treatment 







• Enhances calcium 
excretion
200-500 mL/hr





activity leading to 
decrease bone 
resorption 
60-90 mg IV 
over 2-4 hours 
X 1 dose 









activity leading to 
decrease bone 
resorption 
4 mg IV over 15 
minutes X 1 
dose 





• Flu-like symptoms 
Calcitonin 
• Inhibits osteoclast 
activity 
• Enhances calcium 
excretion
4-8 IU /kg SQ or 







Rosner M, Dalkin A.Clin J Am Soc Nephrol.2012:7;1722-1729.
Thomas SA, Chung S.Jhop.2016:6(1).
Calcitonin (Miacalcin®) 
 FDA approved indications:
 Postmenopausal osteoporosis 
 Hypercalcemia 
 Paget’s disease 
 Hypercalcemia Dosing:
 Dose: 4 units/kg IM/SQ every 12 hrs
 May increase to 8 units/kg every 12 hrs
if response is unsatisfactory 
 Concerns with overuse of 
calcitonin:
 Hypocalcemia
 Tachyphylaxis:  Hypocalcemic effect 
diminishes within 24 to 48 hours
 Price: 400 units/2 mL (200 units/mL): 
$2,712.09
Purpose 
 To assess the prescribing 
practices of calcitonin at Baptist 
Hospital of Miami (BHM) and to 
optimize the utilization of 
calcitonin in patients with 
hypercalcemia.
 The intent of this project is to 
facilitate the implementation of 
a calcitonin prescribing criteria 
through pharmacist review and 
clinical recommendations at 
BHM
Project design 
 Phase I: 
 Retrospective chart review of all patients who received calcitonin injections at Baptist 
Hospital of Miami (BHM) between October 1st, 2017-September 30th, 2019.
 Phase II: 
 Prospective review post implementation of calcitonin prescribing criteria for the 
treatment of hypercalcemia.
 Resident will be on call to determine if initiation of calcitonin meets protocol criteria and 














with IV fluids and IV 
bisphosphonates 

Baseline Demographics  
Phase I (N=94) Phase II (N=16)
Mean age, years 69 68
Gender – male, n (%) 53 (56.4) 4 (25)
Mild Hypercalcemia, n (%) 13 (13.8) 7 (43.8)
Moderate Asymptomatic Hypercalcemia, n (%) 9 (9.6) 2 (12.5)
Moderate symptomatic Hypercalcemia, n (%) 31 (33) 4 (25)
Severe Hypercalcemia, n (%) 41 (43.6) 3 (18.8)
Demographics  
















Internal Medicine Nephrology Oncology Other
 Phase II: Phase I:
12.5%
31.2%56.3%
Ordering Provider Specialty 
















Phase I Phase II
Duration of Calcitonin Therapy 
≤ 48 hrs > 48 hrs
p= 0.0107
≤ 24 hrs > 24 hrs
68.8% 31.2%
Results: Secondary Outcomes
 Number of pharmacy interventions = 16
 75% acceptance rate 





IV Fluids – n (%) 76 (81) 16 (100) p= 0.0689
IV Bisphosphonates – n (%) 83 (88) 16 (100) p= 0.3613
Pharmacist Interventions 
Severity of Hypercalcemia Discontinuation of Calcitonin
Shorten Duration of 
Therapy Declined
Mild (n=7) 2 3 2
Moderate Asymptomatic (n=2) 0 2 0
Moderate Symptomatic (n=4) N/A 2 2
Severe (n=3) N/A 3 0
ଵଶ ௜௡௧௘௥௩௘௡௧௜௢௡௦ ௔௖௖௘௣௧௘ௗ
ଵ଺ ௧௢௧௔௟ ௜௡௧௘௥௩௘௡௧௜௢௡௦


















Total dose adjustments per severity of hypercalcemia
Number of calcitonin doses initially ordered Number of doses dispensed
Reasons for dispensing calcitonin for 
mild hypercalcemia
Presence of symptoms
Failure to first-line therapy




0 10 20 30 40 50 60 70
Total number of doses dispensed
Total number of doses originally ordered
Total number of doses 
• # of doses reduced by 45%
• # of vials saved: 18
• Calculated cost savings ~$48,000 cost savings 




 Low volume of calcitonin orders due to short duration of phase II
 Inability to accurately assess for presence of symptoms for hypercalcemia
 e.g., fatigue due to hypercalcemia vs. underlying disease 
 Lack of documentation of symptoms 
 Opportunities: 
 Educate pharmacists on optimal calcitonin use and monitoring 
 Establish prescribing criteria to facilitate utilization of calcitonin across Baptist Health-System 
 Develop electronic order-sets for the treatment of hypercalcemia based on severity level 
Conclusion
 Implementation of a calcitonin prescribing criteria through active pharmacist review 
and recommendations can facilitate the optimization of calcitonin use in patients with 
hypercalcemia at BHM and potentially lead to cost savings.   
Post-Assessment
 Which of the following classifications of hypercalcemia is calcitonin recommended 
for? 
A.  Moderate symptomatic hypercalcemia
B.  Severe hypercalcemia 
C.  Asymptomatic moderate hypercalcemia 
D.  A & B 
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